SCHEMBL6445919

SCHEMBL6445919

N#Cc1c(NCc2ccccc2)nc(N)nc1-c1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 7/20 0.51
HPGD P15428 4/20 0.49
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
CHUK O15111 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 1/20 0.47
APP P05067 1/20 0.47
PDE5A O76074 1/20 0.46
HTT P42858 4/20 0.45
LMNA P02545 2/20 0.45
TSHR P16473 2/20 0.45
MAPT P10636 2/20 0.45
CDK1 P06493 2/20 0.44
MAPK10 P53779 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6444939 0.88 APP (0.53) HIF1AHPGDKDM4EALDH1A1CHUK
SCHEMBL6443145 0.86 HIF1A (0.56) HIF1AHPGDKDM4EALDH1A1MEN1
SCHEMBL6446516 0.85 METAP1 (0.48) HIF1AHPGDKDM4EALDH1A1HTT
SCHEMBL6443545 0.84 ADORA1 (0.63) CHUKAPPADORA2AADORA1
SCHEMBL6441963 0.78 ADORA1 (0.62) HIF1AHPGDKDM4EALDH1A1CHUK
SCHEMBL5040171 0.78 ADORA2A (0.62) HIF1AHPGDKDM4EALDH1A1CHUK
SCHEMBL6444686 0.76 RAB9A (0.42) KDM4EALDH1A1MEN1KMT2ANPC1
SCHEMBL6444971 0.76 ADORA2A (0.64) HPGDKDM4EALDH1A1CHUKMEN1
SCHEMBL5040104 0.76 HTT (0.47) HPGDKDM4EALDH1A1CHUKMEN1
SCHEMBL6446985 0.75 HTT (0.47) HPGDKDM4EALDH1A1CHUKMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 HIF1A 42/4885HPGD 915/4885KDM4E 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.